Ex-CJI Ranjan Gogoi takes oath as Rajya Sabha MP

New Delhi, May 6: The death toll due to COVID-19 rose to 1,694 and the number of cases climbed to 49,391 in the country on Wednesday, registering an increase of 126 deaths and 2,958 cases in the last 24 hours, the Union Health Ministry said.

The number of active COVID-19 cases is 33,514. A total of 13,160 people have recovered and one patient has migrated, it said.

"Thus, around 28.71 per cent patients have recovered so far," a senior health ministry official said.

The total number of cases include 111 foreign nationals.

A total of 111 deaths were reported since Tuesday evening, of which 49 fatalities were reported from Gujarat, 34 from Maharashtra, 12 from Rajasthan, seven from West Bengal, three from Uttar Pradesh, two each from Punjab and Tamil Nadu and one each from Karnataka and Himachal Pradesh, the ministry said.

Of the 1,694 fatalities, Maharashtra tops the tally with 617 fatalities. Gujarat comes second with 368 deaths, followed by Madhya Pradesh at 176, West Bengal at 140, Rajasthan at 89, Delhi at 64, Uttar Pradesh at 56 and Andhra Pradesh at 36.

The death toll reached 33 in Tamil Nadu, 29 in Telengana, while Karnataka has reported 29 fatalities.

Punjab has registered 25 COVID-19 deaths, Jammu and Kashmir eight, Haryana six and Kerala and Bihar four deaths each.

Jharkhand has recorded three COVID-19 fatalities.

Meghalaya, Chandigarh, Himachal Pradesh, Odisha, Assam and Uttarakhand have reported one fatality each, according to the ministry data.

According to the health ministry data updated in the morning, the highest number of confirmed cases in the country are from Maharashtra at 15, 525, followed by Gujarat at 6,245, Delhi at 5,104, Tamil Nadu at 4,058, Rajasthan at 3,158, Madhya Pradesh at 3,049 and Uttar Pradesh at 2,880.

The number of COVID-19 cases has gone up to 1,717 in Andhra Pradesh and 1,451 in Punjab.

It has risen to 1,344 in West Bengal, 1,096 in Telengana, 741 in Jammu and Kashmir, 671 in Karnataka, 548 in Haryana and 536 in Bihar.

Kerala has reported 502 coronavirus cases so far, while Odisha has 175 cases. A total of 125 people have been infected with the virus in Jharkhand and 111 in Chandigarh.

Uttarakhand has reported 61 cases, Chhattisgarh 59 cases, Assam 43, Himachal Pradesh 42 and Ladakh 41.

Thirty-three COVID-19 cases have been reported from the Andaman and Nicobar Islands.

Tripura has registered 43 cases, Meghalaya has reported 12 and Puducherry nine, while Goa has seven COVID-19 cases.

Manipur has two cases. Mizoram, Arunachal Pradesh and Dadar and Nagar Haveli have reported a case each.

"Our figures are being reconciled with the ICMR," the ministry said on its website.

State-wise distribution is subject to further verification and reconciliation, it said.

Beijing, Mar 21: China reported no domestically transmitted coronavirus cases for the third consecutive day even as seven more fatalities have been confirmed, taking the death toll in the country to 3255.

No new domestically transmitted cases of COVID-19 were reported on the Chinese mainland for the third day in a row on Friday, China's National Health Commission (NHC) said on Saturday.

The overall confirmed cases on the mainland had reached 81,008 by the end of Friday, which included 3,255 who died, 6,013 patients still undergoing treatment, 71,740 patients who had been discharged after recovery, the NHC said.

The NHC said 41 new confirmed COVID-19 cases were reported on the Chinese mainland on Friday from the people arriving from abroad, taking the total number of imported cases to 269.

New Delhi, Jul 6: The Indian Academy of Sciences, a Bengaluru-based body of scientists, has said the Indian Council for Medical Research's (ICMR) target to launch a coronavirus vaccine by August 15 is "unfeasible" and "unrealistic".

The IASc said while there is an unquestioned urgent need, vaccine development for use in humans requires scientifically executed clinical trials in a phased manner.

While administrative approvals can be expedited, the "scientific processes of experimentation and data collection have a natural time span that cannot be hastened without compromising standards of scientific rigour", the IASc said in a statement.

In its statement, the IASc referred to the ICMR's letter which states that "it is envisaged to launch the vaccine for public health use latest by 15th August 2020 after completion of all clinical trials".

The ICMR and Bharat Biotech India Limited, a private pharmaceutical company, are jointly developing the vaccine against the novel coronavirus -- SARS-CoV-2.

The IASc welcomes the exciting development of a candidate vaccine and wishes that the vaccine is quickly made available for public use, the statement said.

"However, as a body of scientists including many who are engaged in vaccine development IASc strongly believes that the announced timeline is unfeasible. This timeline has raised unrealistic hope and expectations in the minds of our citizens," it said.

Aiming to launch an indigenous COVID-19 vaccine by August 15, the ICMR had written to select medical institutions and hospitals to fast-track clinical trial approvals for the vaccine candidate, COVAXIN.

Experts have also cautioned against rushing the process for developing a COVID-19 vaccine and stressed that it is not in accordance with the globally accepted norms to fast-track vaccine development for diseases of pandemic potential.

The IASc said trials for a vaccine involve evaluation of safety (Phase 1 trial), efficacy and side effects at different dose levels (Phase 2 trial), and confirmation of safety and efficacy in thousands of healthy people (Phase 3 trial) before its release for public use.

Clinical trials for a candidate vaccine require participation of healthy human volunteers. Therefore, many ethical and regulatory approvals need to be obtained prior to the initiation of the trials, it added.

The IASc said the immune responses usually take several weeks to develop and relevant data should not be collected earlier.

"Moreover, data collected in one phase must be adequately analysed before the next phase can be initiated. If the data of any phase are unacceptable then the clinical trial is required to be immediately aborted," it said.

For example, if the data collected from Phase 1 of the clinical trial show that the vaccine is not adequately safe, then Phase 2 cannot be initiated and the candidate vaccine must be discarded.

For these reasons, the Indian Academy of Sciences believes that the announced timeline is "unreasonable and without precedent", the statement said.

"The Academy strongly believes that any hasty solution that may compromise rigorous scientific processes and standards will likely have long-term adverse impacts of unforeseen magnitude on citizens of India," it said.